and the expectation is that the price of weight loss pens will be reduced by up to 35% with the entry of generics onto the market.
The projection is from the pharmaceutical company EMS, one of those interested in producing the generic medicine. The company says it was based on the study “The Impact of Competition: evidence of the end of the automatic extension of patents by the STF”, by Cristiano Aguiar Oliveira.
Research commissioned by EMS showed that increased competition leads to a 20% reduction in regulated prices. The effect can reach 35% in larger cases with more competition.
With the loss of the patent, products, such as Ozempic and Wegovy, can be sold by other companies, as long as they are registered with the (National Health Surveillance Agency).
The pharmaceutical company hopes to double the revenue recorded last year with the expansion of supply on the national market, currently worth around R$250 million. And it must manufacture the active ingredient of the medicine in Hortolândia, in the interior of São Paulo.
LINK PRESENT: Did you like this text? Subscribers can access seven free accesses from any link per day. Just click the blue F below.
your subscription could be worth even more
Do you already know the advantages of being a Folha subscriber? In addition to having access to reports and columns, you have exclusive newsletters (). You can also download our free app at or to receive alerts for the day’s top news. Your subscription helps us provide independent, quality journalism. Thanks!
your subscription is worth a lot
More than 180 reports and analyzes published every day. A team with more than 200 columnists and bloggers. Professional journalism that monitors public authorities, conveys useful and inspiring news, counteracts the intolerance of social media and draws a clear line between truth and lies. How much does it cost to help produce this content?
